Literature DB >> 17347555

Efficacy of tonsillectomy plus methylprednisolone pulse therapy for a child with Henoch-Schoenlein purpura nephritis.

Yukihiko Kawasaki1, Kazuhide Suyama, Ayumi Matsumoto, Kei Takano, Koichi Hashimoto, Sigeo Suzuki, Junzo Suzuki, Hitoshi Suzuki, Mitsuaki Hosoya.   

Abstract

Henoch-Schoenlein purpura (HSP) is a systemic disorder characterized by a leukocytoplastic vasculitis involving small vessels with the deposition of immunoglobulin A (IgA) immune complexes. Renal involvement is the principal cause of morbidity and mortality in children with HSP. We report here an 11-year-old boy with Henoch-Schoenlein purpura nephritis (HSPN) accompanied by recurrent purpura and persistent nephropathy despite conventional therapy such as prednisolone, methylprednisolone pulse therapy and immunosuppressive agent (Mizoribine). The patient was treated with tonsillectomy plus methylprednisolone pulse therapy. This treatment decreased proteinuria, induced disappearance of microscopic hematuria, and improved renal pathological findings. Tonsillectomy plus methylprednisolone pulse is effective and useful therapy for some children with recurrent purpura and persistent nephropathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347555     DOI: 10.1620/tjem.211.291

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  10 in total

1.  Clinical remission of Henoch-Schönlein purpura nephritis after a monotherapeutic tonsillectomy.

Authors:  Yoshitaka Iwazu; Tetsu Akimoto; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2010-09-09       Impact factor: 2.801

2.  An adult case of severe steroid-resistant Henoch-Schönlein purpura nephritis treated with intravenous cyclophosphamide and tonsillectomy.

Authors:  Emi Sasaki; Maki Shibata; Asami Kato; Naoto Hamano; Takashi Katsuki; Manami Tada; Fumihiko Hinoshita
Journal:  CEN Case Rep       Date:  2016-07-13

3.  Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.

Authors:  Shinichiro Ohara; Yukihiko Kawasaki; Hiromi Matsuura; Tomoko Oikawa; Kazuhide Suyama; Mitsuaki Hosoya
Journal:  Clin Exp Nephrol       Date:  2011-05-28       Impact factor: 2.801

Review 4.  Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management.

Authors:  Jun-Yi Chen; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2014-12-29       Impact factor: 2.764

Review 5.  The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis.

Authors:  Yukihiko Kawasaki
Journal:  Clin Exp Nephrol       Date:  2011-06-23       Impact factor: 2.801

6.  Efficacy of mizoribine and prednisolone combination therapy in adult patients with IgA vasculitis.

Authors:  Akira Mima
Journal:  Rheumatol Int       Date:  2017-03-02       Impact factor: 2.631

7.  Low-dose corticosteroid with mizoribine might be an effective therapy for elderly-onset ISKDC grade VI IgA vasculitis.

Authors:  Hikaru Sugimoto; Shiho Matsuno; Noriko Yamanaka; Wako Yumura; Mitsuyo Itabashi; Takashi Takei
Journal:  CEN Case Rep       Date:  2020-08-04

8.  Early treatment with methylprednisolone pulse therapy combined with tonsillectomy for heavy proteinuric henoch-schönlein purpura nephritis in children.

Authors:  Hiroaki Kanai; Emi Sawanobori; Anna Kobayashi; Kyoko Matsushita; Kanji Sugita; Kosuke Higashida
Journal:  Nephron Extra       Date:  2011-10-14

9.  Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient.

Authors:  Hiroaki Kanai; Anna Kobayashi; Kyoko Matsushita; Emi Sawanobori; Kanji Sugita; Kosuke Higashida
Journal:  CEN Case Rep       Date:  2013-01-12

10.  Distinct characteristics and outcomes in elderly-onset IgA vasculitis (Henoch-Schönlein purpura) with nephritis: Nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR).

Authors:  Hiroyuki Komatsu; Shouichi Fujimoto; Shoichi Maruyama; Masashi Mukoyama; Hitoshi Sugiyama; Kazuhiko Tsuruya; Hiroshi Sato; Jun Soma; Junko Yano; Seiji Itano; Tomoya Nishino; Toshinobu Sato; Ichiei Narita; Hitoshi Yokoyama
Journal:  PLoS One       Date:  2018-05-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.